什么是轻度认知障碍可靠的等离子体生物标志物? 一项临床4D蛋白质组学研究和验证
Zhitao Hou1,2,3,4, Ailin Sun1,5, Yan Li4
1College of Basic Medical and Sciences Heilongjiang University of Chinese Medicine, Harbin 150040, Heilongjiang, China.
Mediators of inflammation
|June 17, 2024
概括
早期发现阿尔茨海默病 (AD) 和轻度认知障碍 (MCI) 是至关重要的. 这项研究使用蛋白质组分析确定了六种血液生物标志物,这些生物标志物在MCI和AD患者中显示出水平增加,有助于诊断和治疗.
科学领域:
- 生物标志物发现发现
- 神经退行性疾病 神经退行性疾病
- 蛋白质组学是指蛋白质组学.
背景情况:
- 阿尔茨海默病 (AD) 和轻度认知障碍 (MCI) 缺乏有效的治疗方法,强调了早期诊断和干预的必要性.
- 基于血液的生物标志物为非侵入性检测和监测认知衰退提供了一个有希望的途径.
- 蛋白质组分析提供了一个强大的工具,用于识别与疾病进展相关的蛋白质表达的微妙变化.
研究的目的:
- 为早期诊断和评估轻度认知障碍 (MCI) 和阿尔茨海默病 (AD) 的疾病进展确定特定的血液蛋白标记物.
- 评估4D无标签蛋白质学定量分析在血液样本中检测差异蛋白质表达的潜力.
- 通过酶相关免疫吸收试验 (ELISA) 验证已识别的生物标志物,用于临床应用.
主要方法:
- 将参与者招募到三个组:AD,MCI和正常认知控制.
- 在血液样本上利用4D无标签的蛋白质深度定量分析来识别潜在的生物标志物.
- 在扩大样本大小中,使用酶相关免疫吸收试验 (ELISA) 验证了已识别的生物标志物的表达水平.
主要成果:
- 他们确定了六种特定的血液标记物 (APOE,MMP9,UBR5,PLA2G7,STAT5B和S100A8).
- 与正常认知对照组相比,这些标志物在MCI和AD组中呈现出统计学上显著的上调趋势 (P <0.05).
- 在MCI组中,ELISA证实了这些六种蛋白质的水平明显高于对照组,在AD组中,与MCI组相比,AD组的水平进一步升高 (P <0.05).
结论:
- 在健康人群,MCI患者和AD患者中,APOE,MMP9,UBR5,PLA2G7,STAT5B和S100A8的血水平显著不同.
- 这六个生物标志物显示出明显的表达增加趋势,与认知障碍严重程度相关.
- 鉴定出的血标志物对诊断,疾病进展监测以及对认知障碍的治疗策略具有重大潜力.
相关概念视频
Alzheimer's Disease: Overview
462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
120
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
120
Dementia
110
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
110
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
77
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
77
Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179


